Skip to content
The Kids Research Institute Australia logo
Donate

Brain Tumour Research

We strive for a future where no child will die from brain cancer because we have developed new therapies that will cure their disease.

The Brain Tumour Research Laboratory was established in 2011, bringing together the clinic and the laboratory to advance research into childhood brain tumours.

The team is a collaborative group of researchers dedicated to improving our understanding of paediatric brain tumour biology and finding more effective treatments to improve survival rates and quality of life for patients.

The skills of our team members are diverse and include laboratory scientists from academia and industry, clinical oncologists and neuro-surgeons.

Each member of the team brings their unique and varied experience to tackle our research questions. Researchers perform basic and pre-clinical research aimed at identifying the best targets for new therapies and effective new treatments for clinical trials.

Moreover, we collaborate with others who bring valuable expertise. These include, but are not limited to, radiologists (clinical and pre-clinical models), medical physicists (imaging), chemists (drug screening), pharmacologists (pre-clinical testing) and bioinformaticians (large scale analyses of brain tumour genomics).

The team has established a strong national and international reputation and is recognised as being the largest research team in Australia primarily focused on paediatric brain tumours. The major goals of the group are intensely focused on improving the wellbeing of children with cancer.

With strong ties between The Kids and Perth Children's Hospital, the team knows what it takes to get a new treatment into the clinic and their research goals are sharply focused on providing the pre-clinical evidence required to form the basis of new clinical trials.

The overarching scientific goals of our team approach to improving outcomes for children with brain tumours are:

  • Elucidate the molecular basis of different brain tumour types, including medulloblastoma and ependymoma among others, through the analysis of primary patient specimens
  • Improve understanding of the molecular events contributing to these diseases, by analysing the impact of altered signalling pathway activity on the survival, proliferation, invasiveness and tumorigenicity of brain tumour cells
  • Develop novel preclinical models of paediatric brain tumours by relevant targeted genetic mutations to provide systems in which to test new treatments
  • Obtain and test new therapies in appropriate brain tumour models through collaboration with members of the WA Kids Cancer Centre, other academic partners, and industry groups
  • Translate our findings into improved therapies and design of new clinical trials, which we achieve through national and international collaborations with clinical trials consortia such as Australian Children’s Cancer Trials (ACCT) and the Children’s Oncology Group (COG).

Team leader

Brainchild Fellow; Co-Head, Brain Tumour Research

Head of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research Program, The Kids Research Institute Australia

Team members (17)

Dr Annabel Short
Dr Annabel Short

BMedRes (hons), PhD

Pirate Ship Research Fellow

Dr Meegan Howlett
Dr Meegan Howlett

BSc(Hons), PhD

Senior Postdoctoral Researcher and Research Project Manager

Senior Postdoctoral Researcher

Dr Brittany Dewdney
Dr Brittany Dewdney

BSc, MBSc, PhD

Postdoctoral Researcher

Dr Chris Butler

Dr Chris Butler

Postdoctoral Researcher

Dr Zahra Abbas

Dr Zahra Abbas

Postdoctoral Researcher

Hilary Hii

Hilary Hii

Research Officer

Brooke Carline

Brooke Carline

Research Assistant

Jacob Byrne

Jacob Byrne

Research Assistant

Sally Larder

Sally Larder

Research Assistant

Alex Monson

Alex Monson

Research Assistant

Piyusha Johnson

Piyusha Johnson

Research Assistant

Josh Ninan

Josh Ninan

Research Assistant

Hetal Dholaria

Hetal Dholaria

Clinical Fellow (Research) and PhD Student

Brad McCarthy

Brad McCarthy

Medical Student

Adam Byass

Adam Byass

Medical Student

Brain Tumour Research projects

Featured projects

Developing and characterising juvenile models of aggressive paediatric brain cancers for the evaluation of novel immunotherapies.

While profound treatment responses have been realised using immunotherapy for some cancer types, this is yet to be seen for paediatric brain cancer patients.

Finding new, safer and targeted therapies for paediatric brain cancer that amplify responses to radiation therapy

Radiation therapy is an essential component of brain cancer treatment. However, the high doses currently required are extremely damaging to the growing brains and bodies of children.

Publications

Reports and Findings

Show all Reports and Findings

Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma

Chemotherapy often kills a large fraction of cancer cells but leaves behind a small population of drug-tolerant persister cells. These persister cells survive drug treatments through reversible, non-genetic mechanisms and cause tumour recurrence upon cessation of therapy. Here, we report a drug tolerance mechanism regulated by the germ-cell-specific H3K4 methyltransferase PRDM9. 

Factors Associated With Rare Pediatric Cancer Trial Enrollment: A Report From the Children's Oncology Group Rare Tumors Committee

Over 90% of US children with cancer are treated at Children's Oncology Group (COG) centers, which seek to maximize enrollment in therapeutic and biobanking studies. Rare cancers have demonstrated lower than expected COG enrollment. We evaluated trends in COG rare cancer enrollment compared to US incidence from Surveillance, Epidemiology, and End Results (SEER) registries, examining the impact of COG therapeutic trials and Project:EveryChild, a cancer biobank/registry.

IDH mutant high-grade gliomas

Gliomas are the most common type of malignant primary central nervous system (CNS) tumors, resulting in significant morbidity and mortality in children and adolescent and young adult (AYA) patients. The discovery of mutations in isocitrate dehydrogenase (IDH) genes has dramatically changed the classification and understanding of gliomas.  IDH mutant gliomas have distinct clinical, pathological, and molecular features including a favorable prognosis and response to therapy compared to their wildtype counterparts.

Boosting the influenza vaccine schedule in children with cancer: a prospective open-label study

Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule.

Show all